News Release from Patheon Inc.,
(TSX:PTI): PATHEON WINS 2010 EUROPEAN OUTSOURCING AWARD FOR MOST EFFECTIVE TECHNOLOGY TRANSFER
RESEARCH TRIANGLE PARK, N.C., Oct. 7 /CNW/ - Patheon (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry announced today that it has been awarded a 2010 European Outsourcing Award for the most effective scale-up/technology transfer. The award focuses on capacity issues or transfer from lab to full-scale production.
Wes Wheeler, Patheon's Chief Executive Officer and President stated, "It is a great honor to be recognized among many leaders in our industry. This award demonstrates our experience in managing and completing technology transfers within a very compressed timeframe, with no interruption of supply, no decrease in quality, and exceeding the new regulatory standards. Our clients generally choose us over our competition for our state-of-the-art of the facilities, specializing in sterile production, and for our expert knowledge of aseptic filling and terminal sterilization. Paradoxically, we are receiving this award as we launch a new promotion program to eliminate up-front technology transfer costs for any guaranteed volume lyophilization commercial agreement."
This award is given each year by an E.U.-based committee of industry experts. It honors companies that have shown evidence of an innovative, cost-effective and regulatory compliant partnership that effectively brought a product to market and maintained the strict criteria of safety, efficacy and consistency. Judges selected Patheon among numerous competitors after a rigorous selection process.
Patheon was also finalist for the European Outsourcing Award in the Best Contract Manufacturing Project category.
Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. It provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. The company uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Its comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Its integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, ensures that customer products can be launched on-time and with confidence anywhere in the world.
For further information: Patheon Contacts: Wes Wheeler, President & Chief Executive Officer, Tel: (919) 226-3200, Email: email@example.com; Eric Evans, Chief Financial Officer, Tel: (919) 226-3200, Email: firstname.lastname@example.org; Wendy Wilson, Investor Relations and Corporate Communications, Tel: (919) 226-3313, Email: email@example.com